爱美客(300896) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 reached ¥389,636,635.96, an increase of 75.09% year-over-year, and total revenue for the year-to-date was ¥1,023,097,508.89, up 120.29% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥283,441,129.32, representing a 98.01% increase year-over-year, with year-to-date net profit at ¥708,913,425.63, up 144.09%[4] - Sales revenue for the first nine months of 2021 reached CNY 1,027,185,645.09, an increase of 119.08% compared to CNY 468,861,836.99 in the same period of 2020[9] - Net profit for Q3 2021 was CNY 708,448,215.30, representing a 147.98% increase from CNY 285,689,194.18 in Q3 2020[9] - Total profit for Q3 2021 was CNY 831,172,090.87, reflecting a 149.14% increase from CNY 333,613,256.67 in Q3 2020[9] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥671,892,622.78, reflecting a significant increase of 159.67% compared to the previous year[5] - Cash flow from operating activities increased by 119.08% to CNY 1,027,185,645.09 in the first nine months of 2021[10] - Operating cash inflow for Q3 2021 was CNY 1,076,003,257.05, a significant increase from CNY 479,027,069.56 in Q3 2020, representing a growth of approximately 124.9%[25] - The company reported a net cash inflow from operating activities of CNY 671,892,622.78 for Q3 2021, compared to CNY 258,746,301.20 in Q3 2020, marking an increase of approximately 159.5%[25] Assets and Liabilities - Total assets as of September 30, 2021, were ¥4,983,968,303.65, an increase of 7.58% from the end of the previous year[5] - The company's total assets as of September 30, 2021, are 4,983,968,303.65 yuan, compared to 4,632,668,833.13 yuan at the end of 2020[18] - Total liabilities increased to CNY 199,470,415.20 from CNY 101,444,659.98, showing a growth of approximately 96% year-over-year[21] - The company’s total liabilities increased, with accounts payable recorded at CNY 4,559,011.00[29] Equity - The company's equity attributable to shareholders increased to ¥4,784,319,865.23, up 5.53% from the end of the previous year[5] - Total equity attributable to shareholders reached CNY 4,784,319,865.23, up from CNY 4,533,816,111.30, indicating an increase of about 6%[21] - The company reported an unallocated profit of 808,888,734.06, contributing to overall equity stability[30] Research and Development - R&D expenses increased by 86.50% to CNY 61,658,347.65 in Q3 2021, compared to CNY 33,060,460.35 in Q3 2020[9] - Research and development expenses for Q3 2021 totaled CNY 61,658,347.65, which is an increase from CNY 33,060,460.35 in the previous year, reflecting a growth of approximately 86%[21] Investments - Long-term equity investments surged by 2810.91% year-over-year, mainly due to investments in joint ventures during the reporting period[8] - Investment payments amounted to CNY 1,775,652,552.17, a 32.11% increase from CNY 1,344,070,800.00 in the previous year[10] - The company completed an investment of 856 million yuan in Huons Bio, acquiring a 25.42% stake as of September 30, 2021[15] Other Financial Metrics - Basic and diluted earnings per share for Q3 2021 were both ¥1.31, a decrease of 15.48% compared to the same period last year[5] - Other income increased by 269.70% to CNY 4,611,754.18, primarily due to subsidies received[9] - The company reported a significant increase in sales personnel costs, contributing to a 138.83% rise in sales expenses to CNY 100,351,573.40[9] Compliance and Reporting - The company has not reclassified any non-recurring gains and losses as recurring items, ensuring compliance with disclosure regulations[7] - The third quarter report was not audited, indicating preliminary financial data[31]